Larry Hong represents leading global companies in complex business disputes and class actions, often with a cross-border component, in federal and state courts. He represents financial institutions, publicly traded companies, and individuals across a variety of industries, including technology, healthcare, and consumer products. Mr. Hong also represents clients in matters outside of litigation, including arbitration and mediation.

Mr. Hong was previously a judicial intern at the United States District Court for the Southern District of New York and an associate at Latham’s London office.

Mr. Hong has achieved favorable outcomes in the following recent representative matters:  

  • The underwriters of Miniso’s IPO in a securities class action, resulting in complete dismissal (SDNY 2024)
  • Sinovac Biotech Ltd. in shareholder litigation concerning its 2018 PIPE transaction, resulting in dismissal with prejudice (D. Mass. 2023)
  • A Chinese internet security company in a securities class action concerning its take-private transaction, resulting in dismissal of over 99% of claimed damages (SDNY 2023)
  • An exercise equipment company in defeating class certification and achieving a partial dismissal of claims in consumer class action alleging false advertising (SDNY 2023)
  • Mallinckrodt Pharmaceuticals in reorganizing under chapter 11, following numerous contested maters and hotly contested confirmation hearing (Bankr. D. Del. 2022)

Bar Qualification

  • New York


  • JD, Duke University School of Law, 2020
  • MA in Economic Law, Sciences Po Paris, 2020
  • BA in Political Science & Philosophy, Columbia University, 2017

Languages Spoken

  • English
  • Chinese (Mandarin)
  • French